# A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

> **NCT03097003** · — · COMPLETED · sponsor: **Amgen** · enrollment: 124 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT03097003
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-06
- **Primary completion:** 2018-12-20
- **Final completion:** 2018-12-20
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03097003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03097003, "A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03097003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*